Dividends & Buybacks ·
CalciMedica held its 2026 Annual Meeting of Stockholders on August 19, 2026
CALCCalciMedica, Inc.
CalciMedica held its 2026 Annual Meeting of Stockholders on August 19, 2026. Shareholders approved an amendment to the 2023 Equity Incentive Plan, increasing authorized shares by 7,500,000 and adjusting reserve calculations for convertible securities. The board ratified Baker Tilly US, LLP as independent auditor and received advisory approval for executive compensation frequency set to annually through 2032. Crucially, shareholders approved a reverse stock split with a ratio between 1-for-2 and 1-for-10 at the Board's discretion, alongside a corresponding reduction in authorized shares. Stockholders also authorized the issuance of Series A and B Warrants for up to 18,673,429 common shares each under a June 23, 2026 Securities Purchase Agreement, including warrants to directors and officers. CalciMedica operates in the biotechnology industry, developing therapies for inflammatory diseases.